Abnormal expression of dopamine and serotonin transporters associated with the pathophysiologic mechanism of Tourette syndrome

Neurology India

Volumn 58, Issue 4, 2010, Pages 523-529

  Jijun, Li ^a,b   Zaiwang, Li ^a   Anyuan, Li ^a   Shuzhen, Wang ^a   Fanghua, Qi ^a   Lin, Zhao ^a   Hong, Lv ^a  

^a SHANDONG UNIVERSITY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

DAT; Pathophysiology; SERT; Tourette syndrome

Indexed keywords

DOPAMINE TRANSPORTER; MESSENGER RNA; SEROTONIN TRANSPORTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; ENZYME LINKED IMMUNOSORBENT ASSAY; GILLES DE LA TOURETTE SYNDROME; IMMUNOFLUORESCENCE; MALE; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANALYSIS OF VARIANCE; ANIMAL; BLOOD; CHILD; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROCEDURES; STATISTICS; STEREOTYPY; TIME; WISTAR RAT;

ANALYSIS OF VARIANCE; ANIMALS; CHILD; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; HUMANS; MALE; RATS; RATS, WISTAR; RNA, MESSENGER; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; STATISTICS AS TOPIC; STEREOTYPED BEHAVIOR; TIME FACTORS; TOURETTE SYNDROME;

EID: 77956378291     PISSN: 00283886     EISSN: 19984022     Source Type: Journal    
DOI: 10.4103/0028-3886.68663     Document Type: Article

References (47)

1. Rampello L, Alvano A, Battaglia G, Bruno V, Raffaele R, Nicoletti F. Tic disorders: from pathophysiology to treatment. J Neurol 2006;253:1-15.
2. Nomura Y, Segawa M. Neurology of Tourette's syndrome (TS) TS as a evelopmental dopamine disorder: a hypothesis. Brain Dev 2003;25: 37-42.
3. Leckman J F. Tourette's syndrome. Lancet 2002;360:1577-1586
4. Steeves TD, Fox SH. Neurobiological basis of serotonin-dopamine antagonists in the treatment of Gilles de la Tourette syndrome. Prog Brain Res 2008;172:495-513.
5. Singer HS. Tourette's syndrome: from behaviour to biology. Lancet Neurol 2005;4:149-159
6. Cortese S, Lecendreux M, Bernardo BD, Mouren MC, Sbarbati A, Konofal E. Attention-deficit/hyperactivity disorder, Tourette's syndrome, and restless legs syndrome: the iron hypothesis. Medical Hypotheses 2008;70:1128-1132
7. Liu Z. The epidemiology of Tourette syndrome. Chinese Journal of Practical Pediatrics 2002;17:194-196 (In Chinese)
8. Albin RL, Mink JW. Recent advances in Tourette syndrome research. Trends Neurosci 2006;29:175-182
9. Leckman J F, Zhang H, Vitale A, Lahnin F, Lynch K, Bondi C, et al. Course of tic severity in Tourette syndrome: the first two decades. Pediatrics 1998;102:14-19
10. Singer HS, Reiss AL, Brown JE, Aylward EH, Shih B, Chee E, et al. Volumetric MRI changes in basal ganglia of children with Tourette's syndrome. Neurology 1993;43:950-956
11. Hyde TM, Stacey ME, Coppola R, Handel S F, Rickler KC, Weinberger DR. Cerebral morphometric abnormalities in Tourette's syndrome: a quantitative MRI study of monozygotic twins. Neurology 1995;45: 1176-1182
12. Mink JW. Basal ganglia dysfunction in Tourette's syndrome: a new hypothesis. Pediatr Neurol 2001;25:190-198
13. Peterson BS. Neuroimaging studies of Tourette syndrome: a decade of progress. Adv Neurol 2001;85:179-196
14. Gurevich E V, Joyce JN. Comparison of [3H]paroxetine and [3H] cyanoimipramine for quantitative measurement of serotonin transporter sites in human brain. Neuropsychopharmacology 1996;14:309-323
15. Amara SG, Kuhar MJ. Neurotransmitter transporters: recent progress. Annu Rev Neurosci 1993;16:73-93.
16. Gelernter J, Vandenbergh D, Kruger SD, Pauls DL, Kurlan R, Pakstis AJ, et al. The dopamine transporter protein gene (SLC6A3): primary linkage mapping and linkage studies in Tourette syndrome. Genomics 1995;30:459-463
17. Blakely RD. Physiological genomics of antidepressant targets: keeping the periphery in mind. J Neurosci 2001;21:8319-8323
18. Lucki I, O'Leary O F. Distinguishing roles for norepinephrine and serotonin in the behavioral effects of antidepressant drugs. J Clin Psychiatry 2004;65:11-24.
19. Zhao Y, Sun L. Antidepressants modulate the in vitro inhibitory effects of propofol and ketamine on norepinephrine and serotonin transporter function. J Clin Neurosci 2008;15:1264-1269
20. McQueen JK, Wilson H, Fink G. Estradiol-17 beta increases serotonin transporter (SERT) mRNA levels and the density of SERT-binding sites in female rat brain. Brain Res Mol Brain Res 1997;45:13-23.
21. McDougle CJ, Goodman WK, Leckman J F, Lee NC, Heninger GR, Price LH. Haloperidol addition in fluvoxaminerefractory obsessive-compulsive disorder. A double-blind, placebocontrolled study in patients with and without tics. Arch Gen Psychiatry 1994;51:302-308
22. Müller-Vahl KR, Meyer GJ, Knapp WH, Emrich HM, Gielow P, Brücke T, Berding G. Serotonin transporter binding in Tourette Syndrome. Neurosci Lett 2005;385:120-125
23. Liu X, Wang Y, Li D, Ju X. Transplantation of rat neural stem cells reduces stereotypic behaviors in rats after intrastriatal microinfusion of Tourette syndrome sera. Behav Brain Res 2008;186:84-90.
24. Hida H, Fukuda A, Fujimoto I, Shimano Y, Nakajima K, Hashitani T, Nishino H. Dopamine-denervation enhances the trophic activity in striatum: evaluation by morphological and electrophysio-logical development in PC12D cells. Neurosci Res 1997;28:209-221
25. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates, 3rd edition. San Diego, Academic Press, 1997;29-55.
26. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402-408
27. Leckman J F, Peterson BS, Anderson GM, Arnsten A F, Pauls DL, Cohen DJ. Pathogenesis of Tourette's syndrome. Child Psychol Psychiatry 1997;38:119-142
28. Hoekstra PJ, Anderson GM, Limburg PC, Korf J, Kallenberg CG, Minderaa RB. Neurobiology and neuroimmunology of Tourette's syndrome: an update. Cell Mol Life Sci 2004;61:886-898
29. Wong D F, Brasic JR, Singer HS, Schretlen DJ, Kuwabara H, Zhou Y, et al. Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: clues from an in vivo neurochemistry study with PET. Neuropsychopharmacology 2008;33:1239-1251
30. Fleckenstein AE, Hanson GR. Impact of psychostimulants on vesicular monoamine transporter function. Eur J Pharmacol 2003;479:283-289
31. Kahlig KM, Galli A. Regulation of dopamine transporter function and plasma membrane expression by dopamine, amphetamine, and cocaine. Eur J Pharmacol 2003;479:153-158
32. Frankhauser P, Grimmer Y, Bugert P, Deuschle M, Schmidt M, Schloss P. Characterization of the neuronal dopamine transporter DAT in human blood platelets. Neurosci Lett 2006;399:197-201.
33. Taylor JR, Morshed SA, Parveen S, Mercadante MT, Scahill L, Peterson BS, et al. An animal model of Tourette's syndrome. Am J Psychiatry 2002;159:657-660
34. Singer HS, Hahn IH, Moran TH. Abnormal dopamine uptake sites in postmortem striatum from patients with Tourette's syndrome. Ann Neurol 1991;30:558-562
35. Hwang WJ, Yao WJ, Fu YK, Yang AS. [99mTc]TRODAT-1/[123I] IBZM SPECT studies of the dopaminergic system in Tourette syndrome. Psychiatry Res 2008;162:159-166
36. Seo D, Patrick CJ, Kennealy PJ. Role of serotonin and dopamine system interactions in the neurobiology of impulsive aggression and its comorbidity with other clinical disorders. Aggress Violent Behav 2008;13:383-395
37. Holmes A. Genetic variation in cortico-amygdala serotonin function and risk for stress-related disease. Neurosci Biobehav Rev 2008;32:1293-1314
38. Linnoila VM, Virkkunen M. Aggression, suicidality, and serotonin. J Clin Psychiatry 1992;53:46-51.
39. Sandor P. Pharmacological management of tics in patients with TS. J Psychosom Res 2003;55:41-48
40. Meyer P, Bohnen NI, Minoshima S, Koeppe RA, Wernette K, Kilbourn MR, et al. Striatal presynaptic monoaminergic vesicles are not increased in Tourette's syndrome. Neurology 1999;53:371-374
41. Heinz A, Knable MB, Wolf SS, Jones DW, Gorey JG, Hyde TM, et al. Tourette's syndrome: [I-123] β-CIT SPECT correlates of vocal tic severity. Neurology 1998;51:1069-1074
42. Stamenkovic M, Schindler SD, Asenbaum S, Neumeister A, Willeit M, Willinger U, et al. No change in striatal dopamine re-uptake site density in psychotropic drug naive and in currently treated Tourette's disorder patients: a [(123)I]-beta-CIT PECT-study. Eur Neuropsychopharmacol 2001;11:69-74.
43. Albin RL, Koeppe RA, Bohnen NI, Nichols TE, Meyer P, Wernette K, et al. Increased ventral striatal monoaminergic innervation in Tourette syndrome. Neurology 2003;61:310-315
44. Malison RT, McDougle CJ, van Dyck CH, Scahill L, Baldwin RM, Seibyl J P, et al. [123I]β-CIT SPECT imaging of striatal dopamine transporter binding in Tourette's disorder. Am J Psychiatry 1995;152:1359-1361
45. Müller-Vahl KR, Berding G, Brücke T, Kolbe H, Meyer GJ, Hundeshagen H, et al. Dopamine transporter binding in Gilles de la Tourette syndrome. J Neurol 2000;247:514-520
46. Cheon KA, Ryu YH, Namkoong K, Kim CH, Kim JJ, Lee JD. Dopamine transporter density of the basal ganglia assessed with [123I]IPT SPECT in drug-naïve children with Tourette's disorder. Psychiatry Res 2004;130:85-95.
47. Parsey RV, Hastings RS, Oquendo MA, Huang YY, Simpson N, Arcement J, et al. Lower serotonin transporter binding potential in the human brain during major depressive episodes. Am J Psychiatry 2006;163:52-58